D. D. Ho

The paper determines structures of three VH1-2-derived antibodies in complex with SARS-CoV-2 spike, revealing modular recognition mechanisms and conformational changes.

This study identifies potent SARS-CoV-2 neutralizing antibodies targeting the N-terminal domain (NTD) and reveals they bind a common supersite on the spike protein.

This study identifies a public antibody class, IGHV3-53/3-66, with potent SARS-CoV-2 neutralization capabilities through paired heavy and light chain interactions.

This study develops VLP-based vaccines targeting the HIV-1 FP8 epitope, showing they induce high-titer FP8-specific antibodies and effective neutralizing responses in mice.

This study finds that patients with severe SARS-CoV-2 disease have higher antibody titers against viral proteins and neutralization capabilities compared to less severe cases.

This study uses smFRET to observe real-time conformational dynamics of SARS-CoV-2 spikes on virus particles, revealing multiple states and mechanisms of neutralization by antibodies and convalescent plasma.

This study shows that ACE2 is a target of the γ-secretase complex, leading to the release of a soluble C-terminal fragment and altered trafficking of ACE2.

This paper introduces a cell-based assay to identify coronavirus 3CL protease inhibitors without live virus, demonstrating its effectiveness through compound screening and structure-activity profiling.

The paper identifies three structurally diverse compounds as inhibitors of the SARS-CoV-2 3CL protease and provides structural insights for inhibitor design.

The paper isolates and characterizes 61 SARS-CoV-2-neutralizing monoclonal antibodies from infected patients, identifying potent antibodies targeting multiple epitopes on the spike protein.

This paper uses cryo-EM to show how SARS-CoV-2 spike protein undergoes pH-dependent structural changes that affect ACE2 binding and antibody evasion.

The paper develops biotin-labeled SARS-CoV-2 spike molecular probes using structure-based design and purification methods, achieving high yields and enabling antibody characterization.

This study uses hPSC-derived lung organoids to identify FDA-approved drugs that inhibit SARS-CoV-2 entry and reduce infection in a model of human COVID-19.

This study uses human pluripotent stem cell-derived colonic organoids to identify drugs that block SARS-CoV-2 infection, finding mycophenolic acid and quinacrine dihydrochloride effective in vitro and in vivo.